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          Activation of the renin angiotensin system (RAS) is a well-known driving force, 
governing the aggravation and progression of CVD and associated target organ damage. 
Angiotensin (Ang) converting enzyme 2 (ACE2), a new member within the RAS family, 
was first cloned from the ventricle of patient with heart failure. ACE2 was shown to be 
upregulated under pathological conditions. We hypothesize that loss of ACE2 negatively 
affects cardiac function and exacerbates hypertrophic cardiomyopathy and aortic 
remodeling in response to Ang II. Eight weeks old ACE2 knock out (KO) and wild type 
(WT) mice were infused with Ang II s.c. (1000 ng/kg/min for 4 weeks) using osmotic 
pumps. Blood pressure (radiotelemetry), cardiac function (echocardiography) and 
cardiac/aortic structural damage (histology) were examined. At baseline before Ang II, 
ACE2 KO displayed a normal phenotype for cardiac function and blood pressure. After 4 
weeks of Ang II infusion, the mean arterial pressure (MAP) was increased (~40% in WT 
and ~33% in ACE2 KO) with no differences between groups. However, ACE2 KO 
responded differently to the increased MAP. Cardiac function analysis revealed severe 
myocardial dysfunction shown by the lowered EF% (31% vs. 13%) as well as FS% (30% 
vs 6%) in ACE2 KO vs WT, respectively. In addition, the cardiac dysfunction was 
associated with hypertrophic cardiomyopathy shown by the increased left ventricular wall 
thickness as well as heart weight/ body weight ratio. Moreover, collagen staining in the 
myocardium and aorta revealed higher collagen percentage in ACE2 KO which indicates 
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cardiovascular remodeling. Furthermore, results showed enhanced oxidative stress in the 
myocardium and aorta of Ang II infused ACE2 KO compared to Ang II WT. In 
conclusion, ACE2 attenuates myocardial maladaptive hypertrophy and cardiovascular 
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Renin Angiotensin System (RAS): 
There is speculation that cardiovascular disease (CVD) will be the leading cause of death 
by 2020 (Burrell, Johnston, Tikellis, & Cooper, 2004). Activation of the renin 
angiotensin system (RAS) is well-known as the driving force that governs aggravation 
and progression of CDV and the associated target organs damage. The release of 
Angiotensinogen hormone from the liver is the precursor from which the subsequent 
hormone peptides, namely Ang I and Ang II by the action of renin and Angiotensin (Ang) 
Converting Enzyme (ACE), respectively, will be formed. Inhibition of Ang II formation 
or subsequent binding to the AT1 receptor is a key target in current pharmacotherapeutics 
for CVD.  
Renin was first reported to be the causative agent of hypertension in hypertensive rats in 
1898  (Kunikullaya, Ananthakrishnan, & Goturu, 2011). Later on, in1934, Goldblatt et 
al., found that hypertension in animal models induced by renal ischemia caused a release 
of vasoconstrictor substance (Goldblatt, Lynch, Hanzal, & Summerville, 1934). After 
that, two independent groups were the first to report the end product of this cascade in 
1939 and they named it as “Hypertensin” (Fasciolo, Houssay, & Taquini, 1938) and 
“Angiotonin” (Page, 1939), separately. Soon after, the two groups agreed on a common 
nomenclature of the vasopressor end product of renin activity as (angiotensin) (Braun-
Menendez & Page, 1958). It was not till 1956 when today’s RAS was described (Skeggs., 
Kahn, & Shumay, 1956). Angiotensin Converting Enzyme (ACE) was first discovered in 
the plasma (Skeggs, Jr. et al., 1956). As a result, the conversion of Ang I to Ang II was 
thought to take place predominantly in the plasma. However, it was found that most of 
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Ang II formation occurs in the pulmonary circulation rather than in the plasma (Ng & 
Vane, 1967). The main antihypertensive effect of ACE inhibitor is mediated by 
decreasing plasma Ang II level (Melaragno & Fink, 1996).  
Angiotensin II 
As a main member in the renin angiotensin system (RAS), Angiotensin (Ang) II, also 
known as Ang (1-8) 1046 m/z, is one of the essential hormone peptides that regulate 
hemodynamic body functions. It has a wide variety of effects on various body organs. In 
addition, its overproduction is responsible for the progression and complication of most 
of cardiovascular disorders. Research studies have been conducted over decades trying to 
explore the effects of this harmful substance on body organ function.  
The exact role of Ang II in the complication of CVD has been studied for decades. Long-
term Ang II infusion is often used as an experimental model for essential hypertension, 
resulting in a gradual and sustained increase in blood pressure and multiple organ 
pathologies (Kirchhoff et al., 2008; Xu, Zhi, Hou, Cohen, & Jiang, 2011; Ruiz-Ortega et 
al., 2001a).  The way in which Ang II induces hypertension has been explained by many 
mechanisms, including increasing peripheral vascular resistance, stimulating electrolyte 
and fluid retention either directly through Ang II type I (AT1) receptor (de Gasparo, 
2002), or indirectly by stimulating aldosterone and vasopressin secretion. Excessive Ang 
II has deleterious effects on myocardium by a plethora of mechanisms such as increasing 
sarcolemmic permeability and death of cardiac myocytes or increasing permeability and 
destruction of coronary microvascular endothelial cells (Gavras & Gavras, 2002a). Other 




receptor activation and the subsequent formation of ROS (Kassiri et al., 2009a) or via 
endothelin-1 peptide activation (Xia & Karmazyn, 2004). It has been documented that 
cardiac myocytes undergo hypertrophy as well as fibrosis associated with collagen 
production in response to Ang II both in vivo (Grobe et al., 2007) and in vitro (Wang et 
al., 2010).  
Ang II infusion is associated with increased pro-inflammatory mediators in the vascular 
smooth muscle cells (Ruiz-Ortega et al., 2001b). In addition, AT1 receptor activation 
mediates a growth response in several cell types, in particular, endothelial cells and 
cardiomyocytes (de Gasparo, Catt, Inagami, Wright, & Unger, 2000). Moreover, AT1 
receptor blockers are effective in decreasing interstitial cardiac fibrosis in the failing heart 
(De Mello & Specht, 2006). A study of the effects of Ang II in adult rats showed 
myocyte hypertrophy and midmyocardial interstitial fibrosis (Grobe et al., 2007). Ang II 
mediated cardiac remodeling is facilitated through myocardial AT1 receptors and 
subsequent intracellular signaling (Browe & Baumgarten, 2004; de Gasparo et al., 2000). 
Interestingly, cardiac Ang II overexpression is associated with left ventricular 
hypertrophy, yet is independent of the effects of pressure overload (Mazzolai et al., 



















Angiotensin Converting Enzyme 2 (ACE2): 
The discovery of a new member within the RAS family, ACE2 , named due to 40% 
homology and 61% sequence similarity with ACE, by  two different groups in 2000 
(Donoghue et al., 2000; Tipnis et al., 2000) caused much excitement in the field of CVD 
pharmacotherapy. The main action of ACE2 is to shuttle Ang II and to tip the balance 
toward Ang (1-7) formation (Xu, Sriramula, & Lazartigues, 2011). Functionally, ACE2 is 
a pleiotropic monocarboxypeptidase and metabolizes a range of peptides (Zhong et al., 
2010). Although its primary action is to convert Ang I to Ang (1-9) (Donoghue et al., 
2000), ACE2 catalytic efficiency is 400-fold higher with Ang II as a substrate than with 
Ang I (Vickers et al., 2002). In addition, the metabolic product of this enzymatic activity, 
Ang (1-7), is a well-known peptide to counteract the deleterious Ang II mediated effects 
(Ferrario, Chappell, Tallant, Brosnihan, & Diz, 1997). Thus, ACE2 is believed to have a  
pivotal role in cardiovascular disease progression as a negative regulator of the RAS 
family. The fact that ACE2 was first found in heart failure ventricles (Donoghue et al., 
2000) and with its predominant expression in the heart (Tipnis et al., 2000), together,  
fueled researchers with tremendous incentives to explore the essential role of this enzyme 
in heart function. 
It has been reported that ACE2 null mice display impaired cardiac contractility function 
in comparison to their control littermates. This result was associated with a severe 
decrease in the percent fractional shortening with higher LVESD and LVEDD in those 
mice , an effect mediated by Ang II, (Crackower et al., 2002; Oudit et al., 2007; 
Nakamura et al., 2008). Two different studies of the ACE2 level in failing hearts showed 
that ACE2 protein level was elevated in the infarcted myocardial tissue (Zisman et al., 
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2003; Kassiri et al., 2009b). Moreover, this increase limits the adverse effects of the 
raised Ang II by an increasing level of vasodilator Ang (1-7) (Burrell et al., 2004). In 
addition, a study of the ACE2 gene in the myocardium of patients with end stage heart 
failure showed that the amount of ACE2 mRNA positively correlated with left ventricular 
end-systolic diameter (Ohtsuki et al., 2010). Despite the variations seen in the phenotype 
of ACE2 null mice with mixed genetic background in the later studies, none of these 
studies negate either the fact that ACE2 is the key pathway for the metabolism of Ang II 
in vivo (Gurley & Coffman, 2008) or that loss of ACE2 aggravates heart failure (Ferreira 
et al., 2010). Collectively, these findings demonstrate that loss of ACE2 is accompanied 















Figure 2. Different enzymatic pathways interfere with RAS. (Modified from 










Traditionally, a diversity of techniques have been elaborated over decades to assess 
cardiac functions including, microangiography, ventricular pressure-volume 
catheterization, and thermo-dilution techniques in mice. However, those techniques are 
invasive since they require instrumentation as well as surgical intervention which limit 
the reliability of serial measurement due to the physiological hemodynamic changes 
(Collins, Korcarz, & Lang, 2003; Pacher, Nagayama, Mukhopadhyay, Batkai, & Kass, 
2008). The quest  for a noninvasive, reliable and reproducible method to assess cardiac 
structure and function in rodents was a challenge for researchers, especially, owing to the 
small heart size and rapid heart rate (around 600 bpm) for those murines (Liu & Rigel, 
2009). The adaptation of echo assessment to murine models is considered an expedient 
technique for the in vivo assessment of cardiac function. Adding to that, the progressive 
enhancement in image acquisition using the merits of the newly developed linear 
transducers with high frequency and the digitalized software for image processing, 
dramatically increased the scope of echo assessment in murines. One of the earliest 
applications of clinical echocardiography was in the evaluation of left ventricular (LV) 
size and function (Picard, Popp, & Weyman, 2008). Moreover, the evolution of the left 
ventricular long-axis measurement and the area measurements of the ventricular contours 
incrementally increased echocardiographic accuracy (Picard et al., 2008). 
Echocardiography (echo) (sonogram of the heart) is a non-invasive, highly reliable, and 
accurate technique for assessment of cardiac structure and function in mice (Tanaka et 
al., 1996; Gao, Dart, Dewar, Jennings, & Du, 2000). Hartley et al. (2002) suggested that 




suitable for murine application (Hartley, Taffet, Reddy, Entman, & Michael, 2002). 
Moreover, in 1995, Gardin et.al was able to assess systolic dysfunction accurately in mice 
(Gardin, Siri, Kitsis, Edwards, & Leinwand, 1995). One of the most commonly used 
methods for echocardiographic procedures is transthoracic echocardiography (TTE), 
which allows the heart to be viewed in 2-Dimension (2-D) by applying a transducer 
directly on the chest. The advantage of TTE over other echocardiographic techniques is 
that it is non-invasive and includes the feasibility to do serial assessment. Each view has 
its own mode from which accurate measurements of the cardiac parameters can be 
obtained. During the parasternal long-axis view, for instance, 2-D mode represents the 
most accurate measurement of the LV mass in mice (Youn et al., 1999). On the other 
hand, short axis 2-D mode and 2-D guided M-mode are recognized as reliable methods in 
identification of impaired systolic function (Tanaka et al., 1996). Pulse Wave Doppler 
(PWD) has been evaluated in many studies to be a reliable method in evaluation of  
mitral valve function, a  strong indicator of LV diastolic function (Sohn et al., 1999; 
Tanaka, 2003; Vlahovic & Popovic, 1999). Furthermore, along with color flow imaging, 
PWD is considered a useful tool in the assessment of cardiac remodeling (Patten, 
Aronovitz, Bridgman, & Pandian, 2002).  
Among the parameters for the assessment of cardiac function, fractional shortening 
(FS%) and Ejection Fraction (EF%) are the most commonly used indexes of global 
systolic function (Liu & Rigel, 2009). Schiller et al. (1996) reported that EF% is the most 
commonly discussed index for LV function  Moreover, Kuecherer et al. (1991) posited 
that EF% has the least variability, and thus, the most reproducible index for the 
evaluation of LV contractility function. FS% has been used for LV systolic function 
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assessment (Gardin et al., 1995). A study done by Gao et al. (2000) on mice heart post 
MI showed that FS% was significantly correlated with LV systolic function and the 
decrease in FS% was parallel with LV enlargement in those mice (Gao et al., 2000). 
Emilsson et al. (2006) suggested there was a good correlation between EF% and FS% 
and thus,  confirmed to be a suitable index for the assessment of LV systolic function 

















2. HYPOTHESIS AND SPECIFIC AIMS 
2.1. Hypothesis 
For this study, it is hypothesized that the loss of ACE2 negatively affects cardiac function 
and exacerbates hypertrophic cardiomyopathy and aortic remodeling in response to Ang 
II. 
2.2. Specific aims 
Two specific aims are associated with this study. 
1. To test the hypothesis that deletion of ACE2 accentuates Ang II mediated cardiac 
dysfunction.  
2. To test the hypothesis that loss of ACE2 enhances Ang II mediated cardiac and 






3. Materials and Methods 
3.1. Experimental protocol:  
Mice (8 weeks old) were anesthetized and telemetric probes were inserted in the carotid 
artery for blood pressure (BP) recording. After a minimum of one week recovery, mice 
were infused with Ang II (1000 ng/kg/min) for 4 weeks using Alzet® osmotic pumps 
(ALZA, CO., Cupertino, CA). Cardiac function and mean arterial pressure (MAP) were 
assessed at baseline and after 4 weeks of Ang II infusion by Echo and telemetry, 
respectively. At the end of the peptide infusion, mice were either decapitated or perfused 
with 4% paraformaldehyde. Hearts and aortas were quickly removed and frozen in liquid 
nitrogen or fixed in 4% paraformaldehyde. All experimental protocols were approved by 
the Wright State University (WSU) Animal Care and Use Committee. Fixed hearts and 
aortas were sent to a commercial laboratory (AML Laboratories, Inc., Baltimore, MD) for 
paraffin embedding, sectioning, and staining. 
3.2. Animals:  
C57Bl/6 male mice (8 weeks old, WT and ACE2 KO, n=7-8 per group) were housed at 
22°C under a 12-hour light/12-hour dark cycle with ad libitum access to tap water and 
standard mouse chow (29% protein, 17% fat, 54% carbohydrate, diet 8640) (Teklad 
Animal Diets, Harlan Labs, USA). ACE2 KO male and ACE2 heterozygous female 
breeding pairs were a gift from Drs. Coffman and Gurley (Duke University). Mice were 
genotyped for ACE2 gene expression. Generation of the C57Bl/6 ACE2 KO strain has 
















3.3. Surgical insertion of radiotelemetric probes:  
Mice were anesthetized with ketamine/xylazine IM (75 mg/kg ketamine and 7.5 mg/kg 
xylazine) (Butler Co., Columbus, OH). A radiotelemetric probe, model TA11PA-C20 
(Data Sciences International, St. Paul, MN) was inserted into left carotid artery and 
advanced into the aortic arch. Carprofene (5mg/kg) (Sigma-Aldrich, St. Louis, MO) was 
administered s.c. for pain management immediately after the surgery and at 24 hrs post-
surgery. Heating pads were used to maintain body temperature and saline drops were 
administered to the eyes periodically to prevent dryness of the sclera. Animals were 
allowed at least one week of recovery before any experiments were conducted.  
3.4. Ang II infusion:  
Ang II (Bachem Inc., Torrance, CA) was dissolved in sterile saline and loaded into 
osmotic pumps (model 1004, ALZA, CO., Cupertino, CA). Pumps were kept at 37 °C in 
sterile saline solution for overnight. The Ang II dose was 1000 ng/kg/min for 4 weeks. 
For pump insertion, mice were anesthetized with isoflurane (3% induction box, 1.5% 
maintenance using a nose cone). Heating pads were used to maintain body temperature. 
The upper back was shaved and cleaned 3x with betadine/70% ethanol. A small 
transverse incision was made between the scapulae and the pump was inserted (cap first) 
in a s.c. pocket on the left lower flank. Carprofen (5 mg/kg) was administered s.c. for 






3.5. Measurement of blood pressure: 
 Radiotelemetry was used to measure BP continuously (500 Hz) for 24 hr periods at 
baseline and during Ang II infusion on a weekly basis. The analysis system used was the 
standard Dataquest A.R.T. system (Data Sciences International, St. Paul, MN).  
3.6. Echocardiography:  
Echocardiographic (Echo) measurements were recorded using a Siemens® ACUSON 
Sequoia 512 ultrasound system (Siemens Medical Solutions USA, Inc., Malvern, PA) 
with an ACUSON 15 megahertz transducer (model 15L8, Siemens Medical Solutions 
Inc., Malvern, PA). Mice were anesthetized with 3% isoflurane in 1 L/min pure oxygen 
(Surgivet Anesco® Isotec 4™). Anesthesia was maintained with 1.5% isoflurane using a 
nose cone. Mice were placed in a supine position and body temperature was maintained 
using a heating pad. Chest hair was removed with an electric shaver and a commercial 
hair removal cream (Nair®, Church & Dwight Co., Inc, Township, NJ). The plate was 
tilted 60 degree anterio-rostrally from the vertical axis. Pre-warmed ultrasound 
transmission gel (Aquasonic™ 100, Parker Laboratories Inc., Fairfield, NJ) was applied 
to the chest. The transducer was positioned at a 90 degree angle to the chest since this 
position provided optimal recordings. 
Initially, 2-Dimentional (2-D) video clips were recorded during the parasternal long axis 
view. The short axis view was then obtained and 2-D video clips as well as 2-D guided 
M-mode (2-D M-mode) images of the interior LV wall were recorded. Images were 
standardized by the aortic annulus and the papillary muscles during the long axis and 
short axis views, respectively. The EF% was calculated based on the end systolic and 
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diastolic volume measurement by the integrative function using the modified Simpson’s 
formula of areas along with major axes (calculated by the Echo). During the transthoracic 
short axis 2-D M-mode, the left ventricular end systolic diameter (LVESd) and end 
diastolic diameters (LVEDd) as well as septal wall thickness (SWT) and posterior wall 
thickness (PWT) were measured. FS% was calculated using the formula FS% = 
[(LVEDd+LVESd)/LVEDd]*100. Whereas the relative wall thickness (RWT) was 
calculated using the formula RWT= [(SWT+PWT)/LVEDd]. Mitral valve function was 
assessed during PWD mode. Images were obtained by tilting the mice backwards 
(posterio-caudally) and directing the probe upward so that the probe was orthogonal with 
the apex of the heart (Respress & Wehrens, 2010). Isovolumetric contraction time 
(IVCT) and isovolumetric relaxation time (IVRT) were also measured. Finally, E-wave 
and A-wave velocities were measured and E/A ratio was calculated. 
3.7. Haematoxylin & Eosin (H&E) staining and cardiomyocyte size quantification: 
Slides containing 5 µm paraffin embedded sections were de-paraffinized  in xylene and 
hydrated by dipping in ethanol 100%, 95%, 80%, 70%, 50%, and water. Then, sections 
were stained with H&E for 15 min, followed by washing in running tap water. Slides 
were allowed to dry on the slide warmer. Finally, sections were cleaned with xylene and 
covered with a Permount® (Fisher Scientific, Pittsburgh, PA). Pictures of the heart 
sections were taken at 20X magnification using a Leica Microsystem® DMR 
microscope. Three separate and random location images of cardiomyocytes were taken in 
the LV wall (images were taken in gray scale). Quantitation was done by Metamorph® 
image analysis software (Ver. 7.6.3) using the Threshold selection tool in combination 




established for the nuclei and for the cardiomyocyte areas. The Area filter was adjusted 
so that  only objects between 30 to 300 pixels  were selected (size selected by measuring 
several nuclei in the control mice), and the Shape filter was set to capture objects with 
circularity between 0.5 – 1 unit. Data were averaged and cell size was computed as total 
tissue area (pixels) per nucleus. 
3.8. Picrosirius Red staining for collagen:      
Paraformaldehyde fixed, paraffin embedded heart and aorta sections (5 µm) were stained 
with Picrosirius Red for visualization of collagen Type I and III. This staining procedure 
was performed in-house (WSU Lab). The method used a Weigert’s iron haematoxylin 
staining kit (ENG Scientific, Inc., Clifton, N.J.). After staining for 8 min, slides were 
washed with tap water and stained with a Picrosirius Red solution containing 5 g of 
Direct Red 80 (Sigma-Aldrich, St. Louis, MO) and 500 ml of saturated picric acid 
solution (Sigma-Aldrich, St. Louis, MO). 
3.9. Picrosirius Red quantification: 
Light microscopic photos were taken at (2.5X) using polarizing light. The advantage of 
polarizing light is the high sensitivity which allows for specific detection of the thin 
collagen fibers. Moreover, this method excludes other possible birefringent fibers. The 
light source transmitter was connected to the microscope’s external port. Polarization was 
achieved using a specific polarizer and analyzer which were set at 90 degrees to each 
other in order to restrict light refraction. A section of a control heart was used to calibrate 
light intensity, plane of polarization, and microscope/camera settings. Once the settings 
were adjusted, they remained constant for all subsequent imaging. Approximately three 
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images were collected for each heart section. Images were taken to include the whole 
heart section in one image. Quantification was done using Metamorph®7.6.3 with the 
threshold selection tool as described previously. The threshold was established by 
adjusting the saturation and intensity of the image to the appropriate level so that it 
selectively traced the collagen fibers. Image sizes were normalized to 700 pixel width and 
the threshold was applied to measure the collagen. Total heart area was measured using 
the trace region selection tool. The collagen volume fraction (CVF %) was computed as a 
percentage to the total section area. Quantification of the aorta was completed using the 
same methods applied to heart. 
3.10. Quantitation of the interior lumen of the aorta: 
Images of sections of the Picrosirius Red stained aorta from both strains were taken at 
2.5X. Images were normalized to the same pixels. Quantitation was done by 
Metamorph® 7.6.3 image analysis software. The luminal areas were traced using the 
trace region selection tool and the selected areas were measured (Pixels).    
3.11. Dihydroethidium (DHE) fluorescence for reactive oxygen species (ROS): 
DHE (Sigma-Aldrich, St Louis, MO) was used to evaluate the in situ superoxide (O2‾) 
level within the myocardium and aorta. DHE is freely permeable to cells and it is 
oxidized to fluorescent ethidium bromide (EB) in the presence of O2‾. EB is a potent 
mutagen and it is trapped intracellularly by intercalation into the DNA. Hearts were 
quickly removed and washed in cold PBS. A 3 mm piece of tissue was trimmed from the 
left ventricle (using a heart block) and frozen in liquid nitrogen. Frozen myocardium 




mmole/L DHE (Sigma-Aldrich, St Louis, MO) in DMSO (Fisher Scientific, Fair Lawn, 
NJ) was prepared as a stock solution. It was diluted to 2 µmole/L in acetone and 10 mM 
of freshly prepared sodium diethyldithiocarbamate (Sigma-Aldrich, St Louis, MO) was 
added to inhibit intracellular or extracellular superoxide dismutase (SOD) activity. 
Sections were incubated with the staining solution at 37°C for 30 min. Sections were 
washed with PBS and cover-slipped using VECTASTIN® hard-set (Vector Laboratories, 
Inc., Burlingame, CA). 
3.12. DHE staining quantification: 
Quantification of the fluorescence was done using Metamorph® 7.6.3. Areas (400 pixel) 
within the myocardium and aorta were selected. The threshold was determined by 
adjusting the intensity level to trace ROS selectively within the myocardium. Regions 
were normalized by the total selected area. 
3.13. Statistical analysis: 
All data are expressed as mean ± SEM. Data were analyzed using STATISTICA® 7.1 
(StatSoft Inc., Tulsa, OK). Significance was achieved when p<0.05. Echo data were 
analyzed using repeated measure 2 way ANOVA. The rationale for using repeated 
measure ANOVA is to compare to assess the treatment effect over the time period for 
both mice strains. The main advantage of this analysis is that it keeps the variability low,  
since each individual serves as his own control. Modified Tukey post hoc test was used to 
compare means. Cardiomyocyte size, collagen, and ROS were evaluated using 
Metamorph® 7.6.3 (Molecular Device, Inc., Sunnyvale, CA) image analysis software as 




4.1. Baseline Cardiac Function and Blood Pressure in ACE2 KO 
Baseline Echo measurements show no differences between WT and ACE2 KO (Figure 
4). Baseline 2D M-Mode Echo analysis shows similar FS% in ACE2 KO as compared to 
WT (Figure 4; a,b). Results from the long axis 2D view show a slight but non- significant 
increase in LVESa in ACE2 KO (Figure 4; c,d). However, there was no difference in the 
calculated EF%. PWD analysis suggested normal diastolic function with no differences 
between strains (Figure 4; e,f). In addition, there was no difference in the baseline mean 
arterial pressure (MAP) between the two strains (Figure 9). Results indicate that ACE2 
null mice exhibit normal phenotype regarding MAP and cardiac function. 
4.2. Cardiac Function and Blood Pressure Post Ang II infusion  
The effect of chronic high dose Ang II infusion (1000 ng/kg/min for 28 days) was 
examined on Echo and BP parameters for both groups (Figure 5). Ang II produced a 
marked reduction in FS% in ACE2 KO, from 40% to 27% (baseline vs. Ang II) (Figure 
6). LVEDd was comparable between groups. However, LVESd and LVESa were 
significantly increased in Ang II ACE2 KO as compared to Ang II WT (Figures 5; a,b). 
The end result was a reduction in EF% of almost 31% in Ang II ACE2 KO as compared 
to 12% (NS) in Ang II WT (Figure 7). Results from the PWD mode showed a lower E/A 
ratio in Ang II ACE2 KO which suggests a diastolic dysfunction (Figure 8). Chronic Ang 
II infusion increased MAP with equal pressor responses in the groups (maximal increase 




in both strains (Figure 10). Results suggest a cardioprotective role of ACE2 against the 
systolic and diastolic dysfunction induced by Ang II infusion. 
4.3. Cardiomyocyte Size Quantitation 
Cardiac cell size was measured in H&E stained tissue using computerized analytical 
methods. Microscopic examination of the cardiomyocytes within the left ventricle 
showed cellular expansion with shrinkage in the intercellular space in the Ang II ACE2 
KO (Figure 11; a,b). Cell size quantitation within the left ventricular wall of Ang II 
ACE2 KO showed remarkably larger cardiomyocyte size than in Ang II WT (Figure 
11c). This indicates cellular hypertrophy in the ACE2 KO. Results are compatible with 
cardiac hypertrophy observed in Ang II ACE2 KO determined by heart to body weight 
ratio (Figure 12; a,b). No differences were seen in the number of counted cells within the 
selected areas in the groups. Collectively, data suggest a defense mechanism of ACE2 
against Ang II induce hypertrophic cardiomyopathy. 
4.4. Evidence for Cardiac and Aortic Fibrosis in Ang II ACE2 KO 
4.4.1. Masson’s Trichrome Staining for Collagen 
Replacement of myocytes with collagenous scar tissue is a major indicator of cardiac 
remodeling. Histological observation of Trichrome stained heart sections showed more 
myocardial collagen in Ang II ACE2 KO than in Ang II WT (Figure 13). The greatest 
collagen density was localized in the left ventricular wall. 
4.4.2. Picrosirius Red Staining for Collagen Fibers     
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The collagen contents within the myocardium and aortic tissues were visualized using 
polarized light imaging of Picrosirius Red stained sections. This type of staining is 
selective for collagen Type I (yellow/orange fluorescence) and Type III (green 
fluorescence). Advantages of the method are high sensitivity, ability to detect thin 
collagen fibers, and to quantify collagen content. Heart and aortic sections were stained 
and images taken using external polarized light. Microscopic observation of myocardium 
showed higher left ventricular collagen content in Ang II ACE2 KO than in Ang II WT 
(Figures 14), (Figure 15). Analysis of collagen content revealed higher (CVF %) in Ang 
II ACE2 KO compared to Ang II WT (Figure 16). Results are consistent to those 
observed with Trichrome staining (Figure 13). 
Examination of the upper ascending thoracic aorta showed a similar enhancement in 
aortic remodeling as seen in the heart. There were marked differences in aortic structure 
and collagen content in Ang II ACE2 KO. Staining with Picrosirius Red revealed a dense 
concentration of collagen fibers in the aortic adventitia of Ang II ACE2 KO (Figure 17). 
Quantification showed a higher percent collagen in Ang II ACE2 KO (Figure 18) 
associated with a narrowing in the luminal vessel area (Figure 19). The high collagen 
content in the outermost layer along with the narrowing area of the aorta would indicate 
vessel stiffness and loss of compliance and elasticity. These changes suggest a greater 
cardiac afterload in Ang II ACE2 KO which compromises systolic function and 
negatively affects EF%. 




Tests were performed to evaluate superoxide (O2‾) production in fresh frozen heart and 
aorta sections using DHE fluorescence staining as the marker. DHE is an efficient 
method to detect in-situ ROS formation (Peshavariya, Dusting, & Selemidis, 2007) and it 
is very selective to O2‾  production (Benov, Sztejnberg, & Fridovich, 1998). Results 
showed that Ang II produced a marked effect on O2‾ production in hearts of ACE2 KO 
(Figures 20). Results were quantified according to the intensity of ROS pixels expressed 
as ROS% to the total section pixels. Myocardial sections from Ang II ACE2 KO 
exhibited higher ROS% compared to Ang II WT (Figure 21). Microscopic examination 
of aorta sections stained with DHE also revealed higher O2‾ levels in Ang II ACE2 KO 
as compared to Ang II WT (Figures 22). Aorta from Ang II ACE2 KO showed higher 
ROS% than Ang II WT (Figures 23). Results suggest that ACE2 may act as a scavenger 










Table 1. Detailed Echo data analysis of cardiac function in the WT and ACE2 KO at the 




WT ACE2 KO Ang II WT 
Ang II ACE2 
KO 
N N=8 N=8 N=7 N=7 
HR(bpm) 410±18 436±22 413±26 446±19 
LVEDa (cm
2
) 0.190±0.004 0.199±0.004 0.191±0.006 0.208±0.006 
LVEDd (cm) 0.376±0.007 0.40±0.007 0.392±0.009 0.398±0.009 
LVESa (cm
2
) 0.129±0.005 0.139±0.005 0.170±0.006† 0.198±0.006†* 
LVESd (cm) 0.226±0.007 0.242±0.007 0.244±0.006 0.284±0.006†* 
FS (%) 40.27±0.8 39.64±0.79 37.85±0.37 27.46±0.36†* 
SWT (cm) 0.068±0.002 0.067±0.002 0.071±0.0037 0.076±0.003 
PWT (cm) 0.072±0.003 0.067±0.002 0.082±0.002 0.091±0.002† 
RWT 0.381±0.016 0.346±0.015 0.394±0.024 0.423±0.024† 
EF (%) 57.8±3.3 57.27±3.35 50.35±1.11 39.52±1.12†* 
E-wave (cm/s) 69.97±2.4 72.94±2.4 55.14±1.65† 52.08±1.65† 
A-wave (cm/s) 38.8±1.44 35.57±1.45 40.64±1.0 40.11±0.97 
E/A Ratio 1.83±0.025 1.80±0.025 1.65±0.011† 1.29±0.012†* 
IVRT (ms) 15.64±0.7 14.95±0.71 18.07±0.5 19.74±0.47† 
IVCT (ms) 19.06±0.76 17.96±0.7 20.9±0.68 21.58±0.7† 
 
Data were analyzed using repeated measure 2 way ANOVA. Modified Tukey post hoc 
test was used to compare means; *p<0.05 vs. WT; † p<0.05 vs. baseline. HR, heart rate; 
LVEDa, left ventricular end diastolic area; LVEDd, left ventricular end diastolic 
diameter; LVESa, left ventricular end systolic area; LVESd, left ventricular end systolic 




thickness; RWT, relative wall thickness; EF%, ejection fraction; E-wave, peak early 










Figure 4: Baseline Echocardiography images of LV in WT (A) and ACE2 KO (B). 
Representative 2D M-Mode images of LV show similar dimensions in the groups. 
Parasternal short axis 2-D images shows similar LV end systolic area (LVESa) in WT (C) 
and ACE2 KO (D). Images were standardized by the aortic annulus and the papillary 
muscles during the long axis and short axis views, respectively. Transmitral pulse wave 





Figure 5: Echocardiographic assessments after 4 weeks of Ang II infusion. 
Representative 2D M-Mode images of LV show an increase in LVESd in ACE2 KO (B) 
as compared to WT (A). Parasternal short axis 2-D images shows an exacerbated LV end 
systolic area (LVESa) in ACE2 KO (D) as compared to WT (C). Images were 
standardized by the aortic annulus and the papillary muscles during the long axis and 
short axis views, respectively. Transmitral pulse wave doppler mode shows a decrease in 






Figure 6: Percent fractional shortening (FS%) at baseline and after 4 weeks of Ang II 
infusion. Results showed decrease in FS% in Ang II ACE2 KO compared to Ang II WT 
and baseline. Data were analyzed using repeated measure 2 way ANOVA. Modified 
Tukey post hoc test was used to compare means; *p<0.05 vs. WT; † p<0.05 vs. baseline. 







    
Figure 7: Percent ejection fraction (EF%) at baseline and after 4 weeks of Ang II 
infusion. Results showed decrease in EF% in Ang II ACE2 KO compared to Ang II WT 
and baseline. Data were analyzed using repeated measure 2 way ANOVA. Modified 
Tukey post hoc test was used to compare means; *p<0.05 vs. WT; † p<0.05 vs. baseline. 






















Figure 8: E/A ratio at baseline and after 4 weeks of Ang II infusion. Results showed a 
decrease in E/A ratio in Ang II ACE2 KO compared to Ang II WT and baseline. Data 
were analyzed using repeated measure 2 way ANOVA. Modified Tukey post hoc test was 
used to compare means; *p<0.05 vs. WT; † p<0.05 vs. baseline. Data are represented as 




























Figure 9: Mean arterial pressure (MAP) in Ang II infused WT and ACE2KO. MAP was 
recorded for 24 hours. Results showed a significant increase in MAP after the first week 
of Ang II infusion with no significant between strains. Data were analyzed using repeated 
measure 2 way ANOVA. Modified Tukey post hoc test was used to compare means; 






























Figure 10: Heart rate (HR) in WT and ACE2 KO. Data was recorded at the baseline and 
after 4 weeks of Ang II infusion. No difference was observed between both strain before 
and after treatment. Data were analyzed using repeated measure 2 way ANOVA. 
Modified Tukey post hoc test was used to compare means. Data are represented as mean± 


















































Figure 11: H&E stained sections within LV wall of Ang II infused WT (A) and Ang II 
infused ACE2 KO (B). Greyscale images were taken at (20X) magnification for 
quantitation purpose. Histological examination showed an increase in the cardiomyocyte 
area with shrinkage in the intercellular space. Image software was used to normalize and 
threshold the images as discussed in the methods section. Cardiomyocyte size was 
computed as (pixel/nuclei) (C). Cell size quantitation shows larger cardiomyocytes area 
in the LV in Ang II infused ACE2 KO vs. Ang II infused WT.  Data were analyzed using 



































































Figure 12: Heart weight/Body weight was computed for both groups after Ang II 
infusion. Results showed higher ratio in ACE2 KO group compared to WT. Data were 































Figure 13: Masson’s Trichrome staining for collagen in myocardial sections in Ang II 
WT (A),(C) and Ang II ACE2 KO (B),(D), at (10X), (20X) magnification, respectively. 
Collagen content (blue) was seen within the interstitial space of Ang II ACE2 KO 















Figure 14: Myocardium sections stained for collagen using Picrosirius Red in Ang II WT 
(A) and Ang II ACE2 KO (B). Tissues were examined using polarized light. Type I 
collagen fibers are highly birefringent, yellow or orange glow. Histological examinations 
showed an overt higher collagen content within the myocardium of ACE2 KO compared 













Figure 15: Myocardium sections stained for collagen using Picrosirius Red in Ang II WT 
(A) and Ang II ACE2 KO (B). Tissues were examined using polarized light. Type I 
collagen fibers are highly birefringent, yellow or orange glow. Histological examinations 
showed an overt higher collagen content within the myocardium of ACE2 KO compared 










Figure 16: Quantitation of myocardial collagen contents of Ang II WT and Ang II ACE2 
KO. Results showed higher collagen volume fraction (CVF%) in Ang II ACE2 KO 
compared to WT. Analysis was done using Metamorph ® 7.6.3 image analysis software 
as described in the method section. Data were analyzed using Unpaired student t-test; 















Figure 17: Sections of aortas were stained with Picrosirius Red in Ang II WT (A) and 
Ang II ACE2 KO (B). Images were taken in polarized light at (2.5X) magnification. 









Figure 18: Quantitation of aortic collagen contents of Ang II WT and Ang II ACE2 KO. 
Results shows that collagen percentage (collagen %) was more than two fold higher in 
Ang II ACE2 KO as compared to Ang II WT. Analysis was done using Metamorph® 
7.6.3 image analysis software as described in the method section. Data were analyzed 







































Figure 19: Quantitation of the luminal area of the aorta showed higher surface area 
(pixels) in Ang II WT than in Ang II ACE2 KO suggesting an aortic stenosis in the 
ACE2 KO mice. Area measurements were done using Metamorph ® 7.6.3 image analysis 
software as described in the method section. Data were analyzed using Unpaired student 







Figure 20: Dihydroethidium (DHE) staining of myocardial sections of Ang II infused 
mice: WT (A) and ACE2 KO (B). Results showed a higher superoxide production within 
the myocardium of Ang II ACE2 KO compared Ang II WT as indicated by DHE 










Figure 21: Quantitation of DHE stained myocardial section revealed a higher ROS% as 
indicated by DHE within the myocardium of Ang II ACE2 KO. This suggests a 
protective role of ACE2 against Ang II induced myocardial oxidative stress. Analysis 
was done using Metamorph® 7.6.3 image analysis software as described in the method 
section. Data were analyzed using Unpaired student t-test; *p<0.05 vs. Ang II WT. Data 






Figure 22: Dihydroethidium (DHE) staining of Aortas of Ang II infused mice: WT (A) 
and ACE2 KO (B). Results showed a higher superoxide production within the aorta of 










Figure 23: Quantitation of DHE stained aortic sections revealed a higher ROS% within 
the aorta of Ang II ACE2 KO. Analysis was done using Metamorph® 7.6.3 image 
analysis software as described in the method section. Data were analyzed using Unpaired 









ACE2 is a monocarboxypeptidase that functions beneficially to reduce the deleterious 
effects of Ang II by metabolizing it to Ang (1-7) (Donoghue et al., 2000; Elased, Cunha, 
Coffman, Gurley, & Morris, 2005; Tipnis et al., 2000; Chappell, Allred, & Ferrario, 
2001). ACE2 has been detected in many organs (Harmer, Gilbert, Borman, & Clark, 
2002) although it is highly expressed in the heart (Donoghue et al., 2000; Tipnis et al., 
2000). To explore ACE2’s role in the development of Ang II induced cardiovascular 
pathologies, the ACE2 KO strain was used (Gurley et al., 2006). The objective was to 
establish the functional and structural outcomes in mice lacking ACE2 and to determine 
the effects of chronic Ang II infusion on BP (radiotelemetry), cardiac function (Echo), 
and cardiac/aortic structure (histology). At baseline conditions, 8 weeks old ACE2 KO 
mice exhibit normal cardiac function. This is consistent with results from Gurley et al. 
(2006) using ACE2 KO mice with the same genetic background, age, and gender.  After 
chronic Ang II stimulation, there were a cadre of symptoms which document ACE2’s 
cardioprotective role. Damage in the Ang II infused ACE2 KO was documented by 
increased cardiac systolic dimensions, overt hypertrophic cardiomyopathy, as well as 
aortic remodeling. These changes were associated with enhanced oxidative stress seen in 
the heart and aorta. Collectively, findings point toward ACE2 as an essential modulator 
to the maladaptive cardiovascular response resulted from long term Ang II stimulation.  
ACE2 was first cloned from the left ventricle of a patient with heart failure (Donoghue et 
al., 2000; Tipnis et al., 2000) and early studies suggested that ACE2 deletion produced 




be a universal finding since there were reports (Gurley et al., 2006; Yamamoto et al., 
2006) that ACE2 KO mice with a mixed genetic background exhibited normal cardiac 
function at the same age. It is worth noting that the cardiac contractile dysfunction 
observed in some ACE2 KO models (Crackower et al., 2002; Oudit et al., 2007; 
Nakamura et al., 2008) might be explained by the methods used for ACE2 gene 
disruption and/or the genetic background (Grobe et al., 2007; Kassiri et al., 2009b; 
Gurley et al., 2006; Gurley & Coffman, 2008). It is also important to consider age as an 
important factor affecting cardiac function of ACE2 KO. A study performed in our 
laboratories showed a cardiac diastolic dysfunction in 48 week old ACE2 KO mice (data 
not shown). Previous studies in ACE2 KO showed that infusion of Ang II caused 
concentric remodeling of the LV associated with mild diastolic dysfunction (Zhong et al., 
2010). The experiments in the present study used a higher pressor dose of Ang II (1000 
ng/kg/min for 4 weeks) to explore the peptide’s effect on blood pressure and myocardial 
capacity in the ACE2 KO. The high dose of Ang II produced a maximal MAP increase of 
almost 42 mmHg with similar changes in the WT and ACE2KO. The BP change was 
associated with a marked deficit in cardiac function in ACE2 KO. In addition to diastolic 
dysfunction, which was seen by the exacerbated E/A ratio, Ang II ACE2 KO exhibited 
severe systolic dysfunction. This was shown by the increase in the LVESd which resulted 
in a decrease in FS% (~30%) and a corresponding decrease in EF% (~32%) in the ACE2 
KO. Thus, the Echo data indicate that ACE2 plays protective role in conserving 
myocardial contractility function against long term Ang II stimulation.  
Ang II infusion raised blood pressure to almost the same extent in both strains. Those 
results could be explained by two theories:  
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 1) Since plasma Ang II is the main factor responsible for the increased BP, the absence 
of a BP effect in ACE2 deletion corresponds to  the fact that ACE2 was not detected in 
the plasma of normal mice (Elased, Cunha, Gurley, Coffman, & Morris, 2006). 
Consistent with that, studies have shown cardiac administration of lentiviral vector 
coding for ACE2 (Diez-Freire et al., 2006) or treatment with recombinant human ACE2 
(Zhong et al., 2010) effectively decreased systolic blood pressure. In contrast, neither 
long term infusion of Ang (1-7) (Grobe et al., 2007; McCollum, Gallagher, & Ann, 2012) 
nor its overexpression (Mercure et al., 2008) could accentuate Ang II’s pressor effects, 
underscoring a role for ACE2, but not plasma Ang (1-7), as a potential agent responsible 
for lowering BP.  
2) The second theory is based on the fact that Ang II can be metabolized by enzymes 
other than ACE2, namely prolylcarboxypeptidase (PCP), prolylendopeptidase (PEP), and 
amino peptidase A (APA) (Grobe, Elased, Cool, & Morris, 2012; Karamyan & Speth, 
2007). Special interest has been paid to APA (Ahmad & Ward, 1990; Nomura et al., 
2005), advocating that these enzymes might be functioning as a stockpile that preserves 
the body from the surplus of plasma Ang II and sustains the elevation in BP even in the 
absence of ACE2.  
Whether it is just the increase in Ang II or the combination with the decrease in its 
metabolite, Ang (1-7), that plays the key role in mediating cardiac dysfunction and 
hypertrophy is still a point of debate. Support is greatest for the first theory (Crackower et 
al., 2002; Nakamura et al., 2008; Nako et al., 2012), however, there is still evidence that 
Ang (1-7) is essential for maintenance of normal cardiac function by counteracting Ang 




from the present study show a protective action of ACE2 against Ang II mediated cardiac 
hypertrophic cardiomyopathy. This was seen by the higher heart weight/ body weight 
ratio in Ang II ACE2 KO as compared to the Ang II WT. In addition, Echo data showed 
an increase in the posterior wall thickness in Ang II ACE2 KO compared to Ang II WT. 
Furthermore, the larger cardiomyocyte size measured within the LV of Ang II ACE2 KO 
mice clearly indicates a role of ACE2 in ameliorating Ang II mediating myocardiocyte 
hypertrophy. Results signify myocardial adaptive effects of ACE2 against hypertrophic 
response resulted from Ang II stimulation.   
There are questions as to the mechanisms by which Ang II induces cardiac injury. One 
proposed mechanism is increased sarcolemmic and microvascular permeability leading to 
cardiac myocyte death (Gavras & Gavras, 2002b). Ang II can also mediate cardiac injury 
through activation of JAK-STAT intracellular signaling which triggers inflammatory and 
remodeling responses (Dostal et al., 1997). Additionally, Ang II can mediate oxidative 
stress via activation of NADPH through AT1R activation and the subsequent formation 
of ROS (Browe & Baumgarten, 2004) or via stimulation of myocardial collagen 
production and secretion (Grobe et al., 2007).  
Ang II induced oxidative stress is likely one of the main mechanisms for peptide 
mediated cardiac damage, acting via AT1R overstimulation (Touyz, 2004; Byrne et al., 
2003). Increased ROS can mediate myocardial hypertrophy and /or remodeling by 
varieties of mechanisms (Takimoto & Kass, 2007; Tsutsui, Kinugawa, & Matsushima, 
2009; Hori & Nishida, 2009).  It has been confirmed that O2‾ is the dominant ROS 
species in ACE2 KO heart (Oudit et al., 2007). Interestingly, Nako et al. reported that 
irbesartan (AT1R blocker) and Tempol (free radical scavenger) display the same 
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cardioprotective effects against Ang II induced cardiac injury (Nako et al., 2012). Present 
study results show that there was enhanced O2‾ production in the myocardium and aorta 
of ACE2 KO mice infused with Ang II. These results are consistent with a study by Oudit 
et al. (2007), which documented myocardial damage in ACE2 KO is mainly mediated by 
Ang II induced oxidative stress (Oudit et al., 2007). The degree of stimulation was 
especially evident in the aorta which showed high levels of DHE in the adventitia. The 
exact role of ACE2 in abrogating ROS formation is not fully understood. One theory is 
that the metabolism of Ang II to Ang (1-7) prevents Ang II induced oxidative stress. 
Another explanation is that ACE2 acts as a scavenger against ROS formation. 
Collectively, these findings emphasize the importance of oxidative stress in Ang II 
induced cardiac and vascular injury.  
Another crucial aspect of Ang II induced cardiovascular pathologies is that Ang II 
stimulation can induce myocardial fibrosis and remodeling (Letavernier et al., 2008; 
Burlew & Weber, 2002). Chronic Ang II treatment stimulates a maladaptive response in 
cardiomyocytes which leads to differential gene expressions, production of ROS, 
impaired calcium cycling (Egger & Domenighetti, 2010), and stimulation of myocardial 
and aortic collagen deposition which are signs of cardiovascular remodeling (Letavernier 
et al., 2008). Using two different types of collagen stains, present results show elevated 
myocardium collagen content in Ang II ACE2 KO. Consistent with that, Zhong et al. 
(2010) reported that Ang II infusion resulted in greater expression of procollagen type 
Iα1. It is plausible that the high collagen and resultant fibrosis seen in ACE2 KO mice 
might result in cardiac stiffness and decreased compliance which are markers for diastolic 




as well as the increased relaxation time seen in Ang II ACE2 KO verify the diastolic 
dysfunction. The structural changes are likely responsible for diminished function, that is, 
the decrease in FS% (more than 30%), and EF% (~31%). Interestingly, results from 
collagen staining in the aorta also suggest a protective effect of ACE2 in this large 
transport vessel. In fact, this is the first report to suggest that the aorta is an important part 
of the Ang II/ACE2 pathological cascade. Vascular fibrosis involves media accumulation 
of extracellular matrix proteins, such as collagen, elastin, fibronectin and proteoglycans. 
Aortas from Ang II ACE2 KO show higher collagen in the adventitia layer along with a 
reduced luminal size area which suggests decreased compliance. This would result in 
aorta stiffness which can negatively affect cardiac afterload and further worsen EF%. 
There is no information on changes in the smaller resistance vessels in ACE2 KO. 
However, since BP is not different between groups, one might suspect that the vascular 
fibrotic changes would be similar. Ang II induced vascular smooth muscle growth, 
arterial remodeling and inflammation associated with cellular growth and calcification is 
well documented (Cheng et al., 2011; Touyz, 2005; Touyz, 2004; Savoia, Burger, 
Nishigaki, Montezano, & Touyz, 2011). It is reasonable that the presence of ACE2 in the 
vascular endothelial cell and arterial smooth muscle cells (Donoghue et al., 2000; 
Hamming et al., 2004) could function protectively in those vessels from the hypertrophic 
effect of Ang II (Hayashi et al., 2010; Jin, Lu, & Lin, 2011). Moreover, it has been shown 
that ACE2 upregulation in the aorta in response to AT1 receptor blocker increased the 
lumen of the aorta in SHR (Igase, Strawn, Gallagher, Geary, & Ferrario, 2005). These 
data suggest specific protective role of ACE2 to the maladaptive cardiovascular 




The RAS system is the driving force that governs the progression and complication of 
CVD and the associated target organ damage. ACE2’s main role is to shuttle the 
vasopressor Ang II and tip the balance toward Ang (1-7) formation. Ang (1-7) has 
beneficial effects since it counteracts Ang II mediated effects. So, ACE2 plays a 
particular protective role as a negative regulator of the RAS. The hypothesis proposed in 
this study was that deletion of ACE2 gene results in enhanced Ang II induce myocardium 
and aortic remodeling.      
Chronic Ang II infusion (1000 ng/kg/min for 4weeks) caused similar elevation in MAP in 
the WT and ACE2 KO mice. However, the elevated MAP was associated with cardiac 
systolic and diastolic dysfunction in ACE2 KO mice but not in the WT group. Cardiac 
dysfunction was shown by the decreased FS% and EF% as well as the lowered E/A ratio 
in Ang II infused ACE2 KO compared to WT. Moreover, results from cardiomyocytes 
size analysis showed an increase in the cardiomyocyte cross sectional area in ACE2 KO 
which is an indication of hypertrophic cardiomyopathy. Consistent with that, heart weight 
/ body weight analysis showed higher ratio in Ang II infused ACE2 KO mice compared 
to WT. Collagen staining results showed an overt higher collagen content within the 
myocardium of Ang II ACE2 KO which indicates a myocardial remodeling. Moreover, 
higher collagen content observed within the adventitial layer of the ascending thoracic 
aorta in ACE2 KO which suggests an aortic remodeling. Furthermore, higher ROS 
formation was observed within the myocardium and aorta of Ang II infused ACE2 KO 
group. In summary, findings support the hypothesis that ACE2 is a crucial enzyme that 




cardiovascular remodeling in mice. This study presents explanations for the protective 
effects of ACE2 against the deleterious effects of Ang II and its cardiac sequelae. The 
work herein magnifies the role of ACE2 as a potential candidate targeting cardiovascular 
disease progression and supports the hypothesis that ACE2 might be a promising avenue 





Echocardiography shows impaired cardiac response to Ang II in ACE2 KO mice 
Mahmoud Alghamri, Nathan Weir, Joshua Miller, Zhongyu Yan, Mark Anstadt, 
Mariana Morris 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University,  Dayton, OH 
Angiotensin converting enzyme 2 (ACE2) is a monocarboxypeptidase that metabolizes 
the potent vasoconstrictor, angiotensin II (Ang II), to the vasodilator, Ang (1-7). Since 
ACE2 is thought to regulate cardiac function, we hypothesized that loss of ACE2 would 
negatively affect cardiac function and alter the response to Ang II. To assess cardiac 
function, echocardiographic (Echo) measurements were made in control and ACE2 
knockout (ACE2 KO) mice under baseline and Ang II stimulated conditions (1000 
ng/kg/min Ang II for 4 weeks). Echos were made using a Siemens® ACUSON system. 
Left ventricular end diastolic and end systolic areas as well as dimensions (LVEDa, 
LVESa, LVEDd and LVESd) were measured during 2-D and M-Modes. Fractional 
shortening (FS) was calculated from M-Mode measurements of left ventricular 
dimensions. Posterior wall thickness (PWT) and septal wall thickness (SWT) were 
measured in M-Mode. Baseline Echos showed higher LVESd in ACE2 KO compared to 
control (0.25 vs 0.22 cm; p<0.05, respectively). This corresponds to a decrease in FS in 
ACE2 KO (0.40 vs 0.35; p<0.05). There was also an increase in the LVESa in ACE2 KO 
compared to control (0.15 vs 0.12 cm2; p<0.05). Chronic Ang II infusion produced an 
initial increase in the mean blood pressure in both groups in the first week (96 to 135 
mmHg in ACE2 KO vs 103 to 145 mmHg in control). This was associated with an 
increase in LVESd in ACE2 KO (~+13%; 0.25 vs 0.28 cm; p<0.001) and controls 
(~+11%; 0.22 vs 0.25 cm; p<0.05). These changes led to a significant decrease in FS in 
ACE2 KO in response to Ang II (~-20%; 0.35 vs 0.28; p<0.05) with no change in 
controls (0.40 vs 0.35; NS). Moreover, LVESa was increased with Ang II treatment in 
ACE2 KO (~+19%; 0.14 vs 0.17 cm2; p<0.01) and controls (~+16%; 0.13 vs 0.15 cm2; 
p<0.01). There were no changes in LVEDa or LVEDd and no signs of dilated wall 
thickness as shown by PWT and SWT. Results suggest a specific cardioprotective role 
for ACE2 at the baseline and after long term Ang II stimulated conditions. 
 
 
Abstract was published in Hypertension (Hypertension. 2011;58:e33-e183). Abstract 





Effect of Chronic Swim Exercise on Adiposity and Metabolic Function in Mice 
Roberta L. Pohlman, Mahmoud S. Alghamari, Ana Carneiro, Lynn Hartzler, L. David 
Mirkin, Vera Farah ,Mariana Morris 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University,  Dayton, OH 
A western diet, high in fat and sugar, causes metabolic and cardiovascular dysfunction.  
The objective was to determine the effect of moderate swimming exercise (1 hr/d, 3 
d/wk, n=9/10 per group) on the metabolic and cardiac responses to a high fat/sugar diet in 
mice.  Groups are: Control (CON); Sedentary (SED, fat/fructose) and Exercise (EX, 
fat/fructose).  Chow (60% fat) and fructose water (10%) were given ad libitum for 8 wk.  
Parameters measured were body fat, heart function (echocardiography, Echo), glucose, 
glucose tolerance (GTT) and liver glycogen.  Mice gained body fat (up to 45%) on the 
fat/fructose diet with no difference between groups.  Metabolic function was improved in 
the EX group as determined by glucose (SED>EX, p<0.01) and GTT (SED>EX, p<0.05) 
Insulin was lower in EX than SED, suggesting improvement in function.  The diet 
increased liver glycogen, an effect which was improved in the EX group.  Echo 
measurements showed impairment in cardiac function in the EX group.  Relative wall 
shortening wa
resulted in a reduced ejection fraction of ~ 37% (EX) vs. 49% (SED).  Data demonstrate 
that a moderate exercise paradigm combined with a high fat/sugar diet improves 
metabolic function, but is detrimental to heart function in morbidly obese mice.   
 




Echocardiography shows impaired cardiac function in ACE2 knockout mice 
Alghamri M, Weir N, Miller J, Anstadt M, Morris M 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University, Dayton, OH 
Angiotensin converting enzyme2 (ACE2) is a monocarboxypeptidase that metabolizes 
the potent vasoconstrictor peptide, angiotensin II (Ang II), to the vasodilator Ang (1-7). 
Since ACE2 is thought to regulate heart function, we hypothesized that loss of ACE2 
would negatively affect function and alter the response to Ang II. Echocardiographic 
(Echo) measurements were made in control and ACE2 knockout (KO) mice under 
baseline and Ang II stimulated conditions (1000 ng Ang II/kg/min for 4 weeks). Echos 
were recorded using a Siemens® ACUSON system. Images of the left ventricle were 
taken in the M-Mode and 2-D Mode. left ventricular end diastolic and end systolic areas 
as well as dimensions (LVEDa, LVESa, LVEDd, and LVESd) respectively, were 
measured. Ejection fraction (EF) was calculated. Posterior wall thickness (PWT) and 
septal wall thickness (SWT) were measured in the M-Mode. Baseline Echo 
measurements show higher lVESa (~+10%) in ACE2KO vs Control. This corresponds to 
a decrease in EF (~-25%). Ang II infusion produced a marked increase in lVESa 
(~+19%) in ACE2KO mice as compared to controls (~+9%). This meant that there was a 
greater decrease in EF in KO mice (~-165%) vs controls (~-125%). There was no sign of 
dilated cardiomyopathy as shown by PWT and SWT measurements. Results suggest a 
protective role for ACE2 in the control of cardiac contractile function under baseline and 
Ang II stimulation. 
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Enhanced Angiotensin II-Induced Cardiac and Aortic Remodeling in ACE2 
Knockout Mice 
Mahmoud Alghamri, Nathan Weir, Mark Anstadt, Khalid Elased, Mariana Morris 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University,  Dayton, OH 
Activation of the renin angiotensin system (RAS) is a well-known driving force, 
governing the aggravation and progression of CVD and associated target organ damage. 
Angiotensin (Ang) converting enzyme 2 (ACE2), a new member within the RAS family, 
was first cloned from the ventricle of patient with heart failure. ACE2 was shown to be 
upregulated under pathological conditions. We hypothesize that loss of ACE2 negatively 
affects cardiac function and exacerbates hypertrophic cardiomyopathy and aortic 
remodeling in response to Ang II. 8 weeks old ACE2 knock out (KO) and wild type 
(WT) mice were infused with Ang II s.c. (1000 ng/kg/min for 4 weeks) using osmotic 
pumps. Blood pressure (radiotelemetry), cardiac function (echocardiography) and 
cardiac/aortic structural damage (histology) were examined. At baseline before Ang II, 
ACE2 KO displayed a normal phenotype for cardiac function and blood pressure. After 4 
weeks of Ang II infusion, the mean arterial pressure (MAP) was increased (~40% in WT 
and ~33% in ACE2 KO) with no differences between groups. However, ACE2 KO 
responded differently to the increased MAP. Cardiac function analysis revealed severe 
myocardial dysfunction shown by the lowered EF% (31% vs 13%) as well as FS% (30% 
vs 6%) in ACE2 KO vs WT, respectively. In addition, the cardiac dysfunction was 
associated with hypertrophic cardiomyopathy shown by the increased left ventricular wall 
thickness as well as heart weight/ body weight ratio. Moreover, collagen staining in the 
myocardium and aorta revealed higher collagen percentage in ACE2 KO which indicates 
cardiovascular remodeling. Furthermore, results showed enhanced oxidative stress in the 
myocardium and aorta of Ang II infused ACE2 KO compared to Ang II WT. In 
conclusion, ACE2 attenuates myocardial maladaptive hypertrophy and cardiovascular 
remodeling in response to long term Ang II stimulation in mice. 
 






Role of angiotensin converting enzyme 2 (ACE2) in body fat and glucose tolerance 
Nathan Weir, Mahmoud Alghamri, Danielle Barnhart, Zhongyu Yan, Khalid Elased, 
Mariana Morris 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University,  Dayton, OH 
Studies in diabetic humans have found dysregulation of the renin angiotensin system 
(RAS), specifically angiotensin (Ang) II.  Angiotensin converting enzyme (ACE) 2 is 
often upregulated as a compensatory enzyme during times of cardiovascular and 
metabolic stress.  We hypothesize global loss of ACE2 will negatively affect glucose 
homeostasis in mice with diet induced obesity. To study this hypothesis, ACE2 knockout 
(KO) and wild type (WT) mice were fed either a 60% high fat (HF) chow for 12 weeks or 
maintained on normal chow (NC). At 8 weeks of age before initiation of the diet, basic 
metabolic parameters were measured using QNMR for body fat analysis. Both strains had 
similar baseline body weight (WT=23.90±0.76, KO=23.70±0.75 g) but KO mice showed 
increased percent body fat [WT=4.51±0.80% (1.08 of 23.91 g), KO=7.01±0.76% (1.66 of 
23.69 g)] and increased fed glucose (WT=147.9±4.53, KO=164.1±5.31 mg/dl). Daily 
caloric intake was comparable between strains (WT=11.84±0.37, KO=11.49±1.27 kcal).  
After 12 weeks of diet, both WT and KO mice had gained significant body weight from 
baseline (WT 13.96, KO=14.63 g) and differences in body fat were eliminated, however, 
glucose handling was altered. Fed glucose showed a main effect for both strain 
(WT=140.31±4.00, KO=156.83±4.23 mg/dl) and diet (NC=141.67±3.78, 
HF=155.48±4.47 mg/dl). Fasted glucose revealed a strain and diet interaction 
(NCxWT=101.11±5.00, NCxKO=94.44±5.00, HFxWT=105.83±6.13, 
HFxKO=138.14±5.67 mg/dl).  Additionally, an intraperitoneal glucose tolerance test 
showed HF KO mice had a significantly elevated area under the curve compared to HF 
WT mice (WT=311.1±20.20, KO=382±18.26 mg/dl/min) while NC WT and NC KO had 
overlapping curves (WT=237.0±9.12, KO=239.0±7.92 mg/dl/min). Plasma analysis 
revealed decreased circulating insulin in NC KO mice (WT=1.1±0.075, KO=0.86±0.056 
ng/ml). High fat diet increased insulin in both strains, but more so in WT (HF 
WT=3.8±0.63, HF KO=3.0±0.61 ng/ml). HF WT mice also demonstrated increased 
pancreas ACE2 activity (NC WT=0.56±0.13, HF WT=2.14±0.5 pmol MCA/µg/h). These 
combined results indicate loss of ACE2 negatively affects glucose homeostasis possibly 
through insulin handling in the pancreas. 
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